| Oct 1 |
Biomea Announces Formation of Global Scientific Advisory Board with 22 World-Renowned Diabetes Experts
|
| Sep 30 |
Biomea Fusion: Recent Rally May Not Last, Despite Upcoming Data Catalysts
|
| Sep 27 |
Biomea upgraded by analysts after FDA lifts clinical hold
|
| Sep 27 |
FDA Removes Clinical Hold On Biomea Fusion's Early-Stage Trials For Potential Diabetes Candidate
|
| Sep 27 |
Biomea’s stock bounces back as FDA lifts clinical hold on diabetes trials
|
| Sep 27 |
IonQ, Biomea Fusion, Rocket Lab USA And Other Big Stocks Moving Higher On Friday
|
| Sep 27 |
BMEA Stock Up 9% as FDA Lifts Clinical Hold on 2 Diabetes Studies
|
| Sep 26 |
Biomea stock jumps 9% after FDA lifts hold on Phase 1/2 study (update)
|
| Sep 26 |
FDA Lifts Clinical Hold on BMF-219 in Type 2 and Type 1 Diabetes Trials
|
| Aug 17 |
With 51% institutional ownership, Biomea Fusion, Inc. (NASDAQ:BMEA) is a favorite amongst the big guns
|
